GNMK - ゲンマ―ク・ダイアグノシス (GenMark Diagnostics Inc.) ゲンマ―ク・ダイアグノシス



symbol GNMK
会社名 GenMark Diagnostics Inc. (ゲンマ―ク・ダイアグノシス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 ゲンマーク・ダイアグノスティクス(GenMark Diagnostics Inc.)は分子診断会社である。同社は複雑医学的状態の診断に役立つマルチプレックス分子検査の開発と商品化に従事する。同社はeSensor電気化学検出技術に基づくマルチプレックス分子試験を開発・商品化する。同社はXT-8機器で実行される4つの食品医薬品局(FDA)除外診断テスト、呼吸器ウイルスパネル、嚢胞性線維症のジェノタイピング試験、ワルファリン感受性試験及び血栓症リスク試験を提供する。同社はまた、C型肝炎(HCV)ジェノタイピング試験及び関連カスタム製造試薬、2C19ジェノタイピング試験を提供する。そのバージョンは研究専用(RUO)XT-8機器に使用できる。XT-8とePlexテスト・カートリッジは個別の電極と複数のシグナル・プローブの組み合わせを利用して、単一サンプルから数十種類のターゲット・バイオマーカーを検出することにより、多重化テストを可能にする。   ゲンマ―ク・ダイアグノシスは、米国の分子診断会社。「XT-8システム」は、独自の電気化学的検出技術を採用しタッチスクリ―ンコンピュ―タ―とアナライザ・ベンチトップ・ワ―クステ―ションで構成される。嚢胞性線維症ジェノタイピング・テスト、ワルファリン感受性試験、血栓リスク試験、呼吸器ウイルス・パネル・テストなどを展開する。   
本社所在地 5964 La Place Court Carlsbad CA 92008-8829 USA
代表者氏名 James Charles Fox ジェームスチャールズフォックス
代表者役職名 Independent Chairman of the Board
電話番号 +1 760-448-4300
設立年月日 40210
市場名 NASDAQ National Market System
ipoyear 2010年
従業員数 517人
EBITDA EBITDA(百万ドル) -48.91600
終値(lastsale) 6.275
時価総額(marketcap) 349850432.675
時価総額 時価総額(百万ドル) 325.59780
売上高 売上高(百万ドル) 63.21100
企業価値(EV) 企業価値(EV)(百万ドル) 298.93680
当期純利益 当期純利益(百万ドル) -57.89000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 GenMark Diagnostics Inc revenues increased 43% to $35.6M. Net loss decreased 12% to $27.9M. Revenues reflect License and other revenue increase of 8% to $143K. Lower net loss reflects Research and development decrease of 34% to $15.9M (expense) Interest Income increase from $106K to $389K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.67 to -$0.50.



   COVID-19 Detection Kits Market | Co-Diagnostics, Inc F. Hoffmann-La Roche AG, Siemens Healthineers AG, Thermo Fisher Scientific, Abbott Laboratories, BGI, Cepheid Inc, BioFire Diagnostics, GenMark Diagnostics  2021/03/23 05:19:10 OpenPR
COVID-19 Detection Kits Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading players
   GENMARK INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GenMark Diagnostics - GNMK  2021/03/17 18:02:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of GenMark Diagnostics (NasdaqGM: GNMK) to F. Hoffmann-La Roche Ltd. Under the terms of the proposed transaction, shareholders of GenMark will receive only $24.05 in cash for each share of GenMark that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or
   3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy  2021/03/16 11:41:00 Benzinga
Roche Holding AG (OTC: RHHBY) acquired GenMark Diagnostics, Inc (NASDAQ: GNMK) in a $1.8 billion deal on Monday, the same day Veracyte …
   Roche, ABD’li rakibi GenMark’ı satın aldı  2021/03/16 11:14:00 Dünya Gazetesi
Roche, ABD merkezli GenMark Diagnostics'i 1.8 milyar dolara satın alarak portföyündeki test boşluğunu doldurdu.
   Stocks making the biggest moves in the premarket: GenMark Diagnostics, AMC Entertainment, Eli Lilly & more - We Beat the Broker  2021/03/15 19:00:00 We Beat the Broker
Take a look at some of the biggest movers in the premarket: GenMark Diagnostics (GNMK) – GenMark will be bought by Swiss drugmaker Roche for $1.8 billion
   GenMark Diagnostics Surges 7% on Preliminary 4Q Results  2021/01/12 14:16:02 Smarter Analyst
Shares of GenMark Diagnostics rose 6.6% in Tuesday’s pre-market trading as the company announced an 84% year-over-year jump in its preliminary fourth-quarter revenue … The post GenMark Diagnostics Surges 7% on Preliminary 4Q Results appeared first on Smarter Analyst .
   Needham Stick to Their Buy Rating for Genmark Diagnostics By  2021/01/11 22:27:25
Needham Stick to Their Buy Rating for Genmark Diagnostics
   Insider Selling: GenMark Diagnostics, Inc. (NASDAQ:GNMK) VP Sells $225,000.00 in Stock  2020/12/25 10:36:59 Watchlist News
GenMark Diagnostics, Inc. (NASDAQ:GNMK) VP Alan Baer Maderazo sold 15,000 shares of the stock in a transaction on Monday, December 21st. The shares were sold at an average price of $15.00, for a total transaction of $225,000.00. Following the transaction, the vice president now owns 230,899 shares in the company, valued at $3,463,485. The transaction […]
   Pfizer's COVID vaccine good for most San Diego stocks but sparks sell-off for biotech rivals, test-makers  2020/11/10 02:01:17 San Diego Union-Tribune
Quidel, GenMark Diagnostics, Arcturus Therapeutics and Inovio Pharmaceuticals among firms that saw shares sink on Pfizer's vaccine data news
   COVID-19 Detection Kits Market - Co-Diagnostics, Inc F. Hoffmann-La Roche AG, Siemens Healthineers AG, Thermo Fisher Scientific, Abbott Laboratories, BGI, Cepheid Inc, BioFire Diagnostics, GenMark Diagnostics, Qiagen  2020/11/06 10:43:32 OpenPR
The COVID-19 Detection Kits research report covers the current scenario and the growth prospects of the global COVID-19 Detection Kits industry forecast 2020 - 2027. The report enlists several important factors, starting from the basics principal to advanced market intelligence
   GenMark Diagnostics to Report Second Quarter 2020 Financial Results on August 4, 2020  2020/07/21 20:05:00 GlobeNewswire
CARLSBAD, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its second quarter…
   GenMark Diagnostics (GNMK) Stock Is a Winner, But How Much Higher Can It Go?  2020/07/10 01:54:26 Smarter Analyst
The coronavirus has had a negative impact on most but as luck would have it, some companies have benefited from the viral outbreak. … The post GenMark Diagnostics (GNMK) Stock Is a Winner, But How Much Higher Can It Go? appeared first on Smarter Analyst .
   Global COVID-19 Detection Kits Market Analysis 2020-2025 Featuring BGI, Cepheid, Abbott, Roche, RayBiotech, BioFire Diagnostics, Co-Diagnostics, GenMark Diagnostics, Qiagen and Randox Labs -  2020/07/01 10:14:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "COVID-19 Detection Kits Market - Growth, Trends and Forecasts (2020-2025)" report has been added to's offering. The Global COVID-19 Detection Kits Market is expected to register a CAGR of 8% during the forecast period. This is attributing increasing incidences of COVID-19 and rising geriatric population globally. According to the World Health Organization, COVID- 19 outbreak declared as a pandemic due to the worldwide spread and severity of d
   GenMark Diagnostics Sees Hammer Chart Pattern: Time to Buy?  2020/05/28 14:30:00 Zacks Investment Research
GenMark Diagnostics has been struggling lately, but the selling pressure may be coming to an end soon.
   Is GenMark Diagnostics (GNMK) Stock a Solid Choice Right Now?  2020/05/26 12:49:00 Zacks Investment Research
GenMark Diagnostics (GNMK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

 関連キーワード  (先端医療機器_テクノロジ― 米国株 ゲンマ―ク・ダイアグノシス GNMK GenMark Diagnostics Inc.)


 twitter  (公式ツイッターやCEOツイッターなど)